Session » ACR Late-Breaking Abstract Poster
- 9:00AM-11:00AM
-
Abstract Number: 7L
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
- 9:00AM-11:00AM
-
Abstract Number: 15L
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients with Osteoarthritis of the Hip or Knee
- 9:00AM-11:00AM
-
Abstract Number: 9L
Circulating Type I, II and III Interferons (IFNs) Associate with IFN-Scores, but Define Distinct Subsets of Active SLE
- 9:00AM-11:00AM
-
Abstract Number: 12L
Evaluation of Intravenous Injection of Tc 99m Tilmanocept in Static Planar Gamma Emission Imaging and Fused SPECT/CT Imaging for Rheumatoid Arthritis
- 9:00AM-11:00AM
-
Abstract Number: 16L
Incidence of Thromboembolic Events in the Tofacitinib Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis and Ulcerative Colitis Development Programs
- 9:00AM-11:00AM
-
Abstract Number: 14L
Miv-711, a Novel Cathepsin K Inhibitor Demonstrates Evidence of Osteoarthritis Structure Modification: Results from a 6 Month Randomized Double-Blind Placebo-Controlled Phase IIA Trial
- 9:00AM-11:00AM
-
Abstract Number: 8L
Prevalence of Blindness in a Cohort of Rheumatologic Patients Treated with Hydroxychloroquine
- 9:00AM-11:00AM
-
Abstract Number: 11L
Risk of Second Malignant Neoplasm and Mortality in Rheumatoid Arthritis Patients Treated with Biological Dmards: A Danish Population-Based Cohort Study
- 9:00AM-11:00AM
-
Abstract Number: 18L
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
- 9:00AM-11:00AM
-
Abstract Number: 13L
Significant, Sustained Improvement in Knee Function after Intra-Articular TPX-100: A Double-Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2 Trial